首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLT3LG |
| Uniprot No | P49771 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-181aa |
| 氨基酸序列 | TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVASNLQD EELCGGLWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQPP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPWSPRPLEA TAPTA |
| 预测分子量 | 17.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural characterization of FLT3 ligand reveals a novel paradigm for receptor binding"** - Lyman, S.D. et al.
摘要：通过X射线晶体学解析FLT3LG的三维结构，揭示其独特的二聚体构象及与FLT3受体结合的特异性机制，为靶向药物设计提供依据。
2. **"Recombinant FLT3 ligand enhances hematopoietic stem cell expansion in vitro"** - Brasel, K. et al.
摘要：研究证实重组FLT3LG在体外显著促进造血干细胞和祖细胞的增殖，并维持其多向分化潜能，为干细胞移植治疗奠定实验基础。
3. **"FLT3 ligand augments immune responses to anti-tumor vaccines in murine models"** - McKenna, H.J. et al.
摘要：在动物模型中，重组FLT3LG作为佐剂增强疫苗诱导的T细胞和树突状细胞活化，显著抑制肿瘤生长，展示其免疫调节潜力。
4. **"Clinical evaluation of FLT3 ligand in mobilizing peripheral blood progenitor cells"** - Maraskovsky, E. et al.
摘要：临床试验表明，重组FLT3LG联合其他细胞因子可有效动员外周血中的造血前体细胞，优化自体移植的细胞采集效率。
FLT3LG (Fms-related tyrosine kinase 3 ligand), also known as Flt3 ligand, is a naturally occurring cytokine critical for hematopoietic and immune system regulation. It is a type I transmembrane protein that can be proteolytically cleaved to release a soluble form. FLT3LG binds to its receptor FLT3 (CD135), a tyrosine kinase receptor expressed on hematopoietic stem cells, progenitor cells, and dendritic cells (DCs). This interaction activates downstream signaling pathways, including PI3K/AKT, MAPK, and STAT, which drive cell proliferation, survival, and differentiation.
Biologically, FLT3LG plays a pivotal role in maintaining hematopoietic stem cell pools and promoting the development of DCs, natural killer cells, and B lymphocytes. Its function in DC homeostasis has made it a focus in cancer immunotherapy research, particularly in enhancing antigen presentation and antitumor immune responses. Clinically, recombinant FLT3LG protein is used ex vivo to expand hematopoietic precursors for transplantation or in combination with vaccines to boost DC-mediated immunity.
Recombinant FLT3LG is typically produced in mammalian expression systems (e.g., CHO cells) to ensure proper glycosylation and bioactivity. Its therapeutic potential is being explored in hematologic malignancies, though paradoxically, FLT3 mutations are also implicated in acute myeloid leukemia (AML), necessitating targeted inhibitors. Current studies investigate its dual role as both a growth factor and an immune adjuvant, highlighting its versatility in regenerative medicine and oncology. Despite its promise, optimal dosing and timing remain challenges to avoid unintended proliferation of malignant clones in certain contexts.
×
